Captrust Financial Advisors grew its position in shares of Eli Lilly And Co (NYSE:LLY) by 0.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 21,627 shares of the company’s stock after purchasing an additional 87 shares during the quarter. Captrust Financial Advisors’ holdings in Eli Lilly And Co were worth $2,503,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund increased its stake in shares of Eli Lilly And Co by 17,720.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock valued at $367,000 after acquiring an additional 42,182,367 shares in the last quarter. FMR LLC increased its stake in shares of Eli Lilly And Co by 526.5% in the 3rd quarter. FMR LLC now owns 7,444,216 shares of the company’s stock valued at $798,838,000 after acquiring an additional 6,255,915 shares in the last quarter. BlackRock Inc. increased its stake in shares of Eli Lilly And Co by 3.0% in the 4th quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock valued at $7,979,649,000 after acquiring an additional 2,030,845 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of Eli Lilly And Co by 54.0% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 4,693,492 shares of the company’s stock valued at $503,659,000 after acquiring an additional 1,644,879 shares in the last quarter. Finally, Jennison Associates LLC increased its stake in shares of Eli Lilly And Co by 59.7% in the 4th quarter. Jennison Associates LLC now owns 3,425,424 shares of the company’s stock valued at $396,390,000 after acquiring an additional 1,280,878 shares in the last quarter. Hedge funds and other institutional investors own 78.69% of the company’s stock.

Shares of LLY stock opened at $128.16 on Thursday. The firm has a market cap of $129.68 billion, a price-to-earnings ratio of 23.09, a price-to-earnings-growth ratio of 2.52 and a beta of 0.33. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38. Eli Lilly And Co has a 12 month low of $74.51 and a 12 month high of $130.75.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.03). The business had revenue of $6.44 billion for the quarter, compared to the consensus estimate of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.14 EPS. Analysts forecast that Eli Lilly And Co will post 5.64 EPS for the current year.

Several research firms have recently weighed in on LLY. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $121.00 price objective for the company in a research note on Wednesday, December 19th. UBS Group began coverage on shares of Eli Lilly And Co in a research note on Wednesday. They issued a “buy” rating for the company. JPMorgan Chase & Co. began coverage on shares of Eli Lilly And Co in a research note on Tuesday, March 12th. They issued an “overweight” rating and a $140.00 price objective for the company. Citigroup lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $115.00 price objective for the company. in a research note on Monday, November 26th. Finally, BMO Capital Markets reiterated a “buy” rating on shares of Eli Lilly And Co in a research note on Wednesday, December 19th. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Eli Lilly And Co presently has a consensus rating of “Buy” and a consensus target price of $113.06.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 4,000 shares of the business’s stock in a transaction on Thursday, January 31st. The shares were sold at an average price of $120.00, for a total transaction of $480,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $127.01, for a total transaction of $127,010.00. The disclosure for this sale can be found here. Insiders have sold a total of 833,190 shares of company stock valued at $102,388,102 in the last 90 days. 0.11% of the stock is currently owned by company insiders.

WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2019/03/21/captrust-financial-advisors-has-2-50-million-holdings-in-eli-lilly-and-co-lly.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: What are economic reports?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.